Events

LSX World Congress w/ Jackie Hunter

Drug Discovery and Development in the Era of AI and Analytics

The life science sector has struggled for years with expensive, inefficient drug discovery and high failure rates in drug development. Now, new technologies like artificial intelligence, machine learning, and data analytics promise to revolutionise biopharma R&D with in-silico drug design, sophisticated analysis of highly complex data sets, and an accelerated path through the clinic and to market. But what is the reality on the ground behind the buzz? Just how remote is the R&D model promoted by AI evangelists, and what are the major hurdles that R&D teams and innovators still must overcome if that model is to become reality? A panel of biopharma R&D transformers discuss the potential of artificial intelligence and data-driven technologies to create a new digital R&D paradigm.

  • “Necessity is the mother of invention” – why is AI so valuable to R&D teams?
  • How successful has innovation in the R&D space been thus far?
  • Commercialising data-driven drug discovery and development technologies

Register here →

Featuring:

Jackie Hunter | Board Member, BenevolentAI

Abraham Heifets | CEO Atomwise

Martin-Immanuel Bittner | CEO, Arctoris

Nick Scott-Ram | Chief of Strategic Development, Sensyne Health

Moderator: Bill Aronson | COO, Artificial Intelligence Research Group


Jackie Hunter

Board Director of BenevolentAI

Jackie Hunter is a Board Director of BenevolentAI.  Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry.

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022